PHARMAC is seeking feedback on a proposal to list insulin aspart (NovoRapid FlexPen) in Section B and Part II of Section H of the Pharmaceutical Schedule from 1 December 2014 through a provisional agreement with Novo Nordisk Pharmaceuticals Limited.

In summary, from 1 December 2014, insulin aspart (NovoRapid FlexPen) would be listed in the community and DHB hospitals at the same price and subsidy as the currently listed presentations of insulin aspart.

For more details, go to: http://www.pharmac.health.nz/news/consultation-2014-10-06-insulin-aspart/